This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. 2019;10(1).Search in Google Scholar
Mills AM, Shanes ED. Mucinous ovarian tumors. Surg Pathol Clin. 2019;12:565-85.Search in Google Scholar
Kubeček O, Laco J, Špaček J, Petera J, Kopecký J, Kubečková A, et al. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis. 2017; 34:295-307.Search in Google Scholar
Dundr P, Singh N, Nožičková B, Němejcová K, Bártů M, Stružinská I. Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics. Diagn Pathol. 2021;16(1):20.Search in Google Scholar
Hollis RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 2023;555:216057.Search in Google Scholar
Ordulu Z, Watkins J, Ritterhouse LL. Molecular pathology of ovarian epithelial neoplasms: predictive, prognostic, and emerging biomarkers. Surg Pathol Clin. 2021;14:415-28.Search in Google Scholar
Dion L, Carton I, Jaillard S, Timoh KN, Henno S, Sardain H, et al. The landscape and therapeutic implications of molecular profiles in epithelial ovarian cancer. J Clin Med. 2020;9:1-12.Search in Google Scholar
Dundr P, Bártů M, Bosse T, Bui QH, Cibula D, Drozenová J, et al. Primary mucinous tumors of the ovary: An interobserver reproducibility and detailed molecular study reveals significant overlap between diagnostic categories. Mod Pathol. 2023;36(1): 100040.Search in Google Scholar
Mehra P, Aditi S, Prasad KM, Bariar NK. Histomorphological analysis of ovarian neoplasms according to the 2020 WHO classification of ovarian tumors: A distribution pattern in a tertiary care center. Cureus. 2023;15(4).Search in Google Scholar
Köbel M, Kang EY. The evolution of ovarian carcinoma subclassification. Cancers. 2022;14:416.Search in Google Scholar
Xu W, Rush J, Rickett K, Coward JIG. Mucinous ovarian cancer: A therapeutic review. Crit Rev Oncol Hematol. 2016;102:26-36.Search in Google Scholar
Talia KL, Parra-Herran C, McCluggage WG. Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approach. Histopathology. 2022;80:255-78.Search in Google Scholar
Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M, et al. Gynecologic cancer intergroup (GCIG) Consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014;24:14-9.Search in Google Scholar
Hart WRMD. Mucinous tumors of the ovary: A review. Int J Gynecol Pathol. 2005;24(1):4-25.Search in Google Scholar
Babaier A, Ghatage P. Mucinous cancer of the ovary: Overview and current status. Diagnostics. 2020;10(1):52.Search in Google Scholar
Nistor S, El-Tawab S, Wong F, Zouridis A, Roux R, Manek S, et al. The clinicopathological characteristics and survival outcomes of primary expansile vs. infiltrative mucinous ovarian adenocarcinoma: a retrospective study sharing the experience of a tertiary centre. Transl Cancer Res. 2023;12(10):2682-92.Search in Google Scholar
Gershenson DM. Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol. 2017;41:49-59.Search in Google Scholar
Song T, Lee YY, Choi CH, Kim TJ, Lee JW, Bae DS, et al. Histologic distribution of borderline ovarian tumors worldwide: A systematic review. J Gynecol Oncol. 2012;24(1):44-51.Search in Google Scholar
Muyldermans K, Moerman P, Amant F, Leunen K, Neven P, Vergote I. Primary invasive mucinous ovarian carcinoma of the intestinal type: Importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. Eur J Cancer. 2013;49(7):1600-8.Search in Google Scholar
Huin M, Lorenzini J, Arbion F, Carcopino X, Touboul C, Dabi Y, et al. Presentation and prognosis of primary expansile and infiltrative mucinous carcinomas of the ovary. J Clin Med. 2022;11(20).Search in Google Scholar
Lee KR, Scully RE. Mucinous tumors of the ovary a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with “pseudomyxoma peritonei”. Am J Surg Path. 2000;24(11):1447-64.Search in Google Scholar
Cobb LP, Gershenson DM. Treatment of rare epithelial ovarian tumors. Hematol Oncol Clin North Am. 2018;32:1011-24.Search in Google Scholar
Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113(3):331-4.Search in Google Scholar
Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C, Dastamani C, Bakalianou K, Liapis A, et al. Metastatic neoplasms of the ovaries: A clinicopathological study of 97 cases. Arch Gynecol Obstet. 2011;284(5):1283-8.Search in Google Scholar
Carr NJFrcp, Cecil TDM, Mohamed FM, Sobin LHM, Sugarbaker PHM, González-Moreno SMP, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia the results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol. 2016;40(1):14-26.Search in Google Scholar
Kelemen LE, Köbel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12(11):1071-80.Search in Google Scholar
Bassiouny D, Ismiil N, Dubé V, Han G, Cesari M, Lu FI, et al. Comprehensive clinicopathologic and updated immunohistochemical characterization of primary ovarian mucinous carcinoma. Int J Surg Pathol. 2018;26(4):306-17.Search in Google Scholar
Hu A, Li H, Zhang L, Ren C, Wang Y, Liu Y, et al. Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality. J Clin Pathol. 2015;68(7):522-8.Search in Google Scholar
Stelow EB, Yaziji H. Immunohistochemistry, carcinomas of unknown primary, and incidence rates. Semin Diagn Pathol. 2018;35(2):143-52.Search in Google Scholar
Li X, Beihua K. PAX8 is a novel marker for differentiating between various types of tumor, particularly ovarian epithelial carcinomas (review). Oncol Lett. 2013;5(3):735-8.Search in Google Scholar
Aldaoud N, Erashdi M, Alkhatib S, Abdo N, Al-Mohtaseb A, Graboski-Bauer A. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm. BMC Res Notes. 2019;12(1).Search in Google Scholar
Gouy S, Saidani M, Maulard A, Bach-Hamba S, Bentivegna E, Leary A, et al. Characteristics and prognosis of stage i ovarian mucinous tumors according to expansile or infiltrative type. Int J Gynecol Cancer. 2018;28(3):493-9.Search in Google Scholar
Yoshikawa N, Kajiyama H, Mizuno M, Shibata K, Kawai M, Nagasaka T, et al. Clinicopathologic features of epithelial ovarian carcinoma in younger vs. older patients: Analysis in Japanese women. J Gynecol Oncol. 2014;25(2):118-23.Search in Google Scholar
Brown J, Frumovitz M. Mucinous tumors of the ovary: Current thoughts on diagnosis and management. Curr Oncol Rep. 2014;16(6).Search in Google Scholar
Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer. 2015;15(1).Search in Google Scholar
Hunter SM, Gorringe KL, Christie M, Rowley SM, Bowtell DD, Campbell IG. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin Cancer Res. 2012;18(19):5267-77.Search in Google Scholar
Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. N Eng J Med. 2019;380(13):1256-66.Search in Google Scholar
Lee YJ, Lee MY, Ruan A, Chen CK, Liu HP, Wang CJ, et al. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms. Oncotarget. 2016;7.Search in Google Scholar
Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med. 2015;7(1).Search in Google Scholar
Bouri S, Simon P, D’Haene N, Catteau X, Noël JC. P53 and PIK3CA mutations in KRAS/HER2 negative ovarian intestinal-type mucinous carcinoma associated with mature teratoma. Case Rep Obstet Gynecol. 2020;2020.Search in Google Scholar
Mueller JJ, Schlappe BA, Kumar R, Olvera N, Dao F, Abu-Rustum N, et al. Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. Gynecol Oncol. 2018;150(1):127-35.Search in Google Scholar
Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229(1):111-20.Search in Google Scholar
Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 2013;231(1):21-34.Search in Google Scholar
Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 74(7353):609-15.Search in Google Scholar
Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012;226(3):413-20.Search in Google Scholar
Iida Y, Okamoto A, Hollis RL, Gourley C, Herrington CS. Clear cell carcinoma of the ovary: A clinical and molecular perspective. Int J Gynecol Cancer. 2021;31:605-16.Search in Google Scholar
Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, et al. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. Br J Cancer. 2017;117(5):717-24.Search in Google Scholar
Bolton KL, Chen D, de la Fuente RC, Fu Z, Murali R, Köbel M, et al. Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin Cancer Res. 2022; 28(22):4947-56.Search in Google Scholar
Friedlander ML, Russell K, Millis S, Gatalica Z, Bender R, Voss A. Molecular profiling of clear cell ovarian cancers: Identifying potential treatment targets for clinical trials. Int J Gynecol Cancer. 2016;26(4):648-54.Search in Google Scholar
Cybulska P, Paula ADC, Tseng J, Leitao MM, Bashashati A, Huntsman DG, et al. Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecol Oncol. 2019;154(3): 516-23.Search in Google Scholar
Pierson WE, Peters PN, Chang MT, Chen L may, Quigley DA, Ashworth A, et al. An integrated molecular profile of endometrioid ovarian cancer. Gynecol Oncol. 2020;157(1):55-61.Search in Google Scholar
Crobach S, Ruano D, Van Eijk R, Fleuren GJ, Minderhout I, Snowdowne R, et al. Target-enriched next-generation sequencing reveals differences between primary and secondary ovarian tumors in formalin-fixed, paraffin-embedded tissue. J Mol Diagn. 2015;17(2): 193-200.Search in Google Scholar
Garg S, Nagaria TS, Clarke B, Freedman O, Khan Z, Schwock J, et al. Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing. Mod Pathol. 2019;32(12):1823-33.Search in Google Scholar
Hodgson A, Howitt BE, Park KJ, Lindeman N, Nucci MR, Parra-Herran C. Genomic characterization of HPV-related and gastric-type endocervical adenocarcinoma: Correlation with subtype and clinical behavior. Int J Gynecol Pathol. 2020;39(6):578-86.Search in Google Scholar
Jang JYA, Yanaihara N, Pujade-Lauraine E, Mikami Y, Oda K, Bookman M, et al. Update on rare epithelial ovarian cancers: Based on the rare ovarian tumors young investigator conference. J Gynecol Oncol. 2017;28(4):e54.Search in Google Scholar
Craig O, Salazar C, Gorringe KL. Options for the treatment of mucinous ovarian carcinoma. Curr Treat Options Oncol. 2021;22(12): 114.Search in Google Scholar
Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, et al. Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol. 2020;156(3):552-60.Search in Google Scholar
Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: Pooled analysis from seven randomized controlled trials. Oncologist. 2013;18(9):1004-12.Search in Google Scholar
Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: A systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer. 2012;12:89.Search in Google Scholar
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-8.Search in Google Scholar
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Eng J Med. 2011;365(26):2484-96.Search in Google Scholar
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Eng J Med. 2011;365(26):2473-83.Search in Google Scholar
Aghajanian C, Blank S V., Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-45.Search in Google Scholar
Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009;113(1):21-7.Search in Google Scholar
Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol. 2008;110(2):140-5.Search in Google Scholar
Sato N, Saga Y, Mizukami H, Wang D, Fujiwara H, Takei Y, et al. Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations. Oncol Rep. 2012;27(5):1336-40.Search in Google Scholar
McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433.Search in Google Scholar
Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal. Cancer. 2011;117(3):554-62.Search in Google Scholar
Perfil de Orcid